2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

•Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics.•The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting.•The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates.•Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade).•All recommendations are for the first course of antineoplastic therapy; modifications may be needed in subsequent courses.